INOVIO (NASDAQ: INO) has announced that it will release its fourth-quarter and year-end 2024 financial results on March 18, ...

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

Inovio Pharmaceuticals Inc. closed 86.91% short of its 52-week high of $14.75, which the company reached on April 1st.

Inovio Pharmaceuticals Inc. closed 86.10% short of its 52-week high of $14.75, which the company achieved on April 1st.

The Global Inhaled Nitric Oxide Market is valued at approximately USD 1.12 billion in 2023 and is projected to experience robust growth with a compound annual growth rate (CAGR) of more than 7.70% ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Shares of Inovio Pharmaceuticals stock opened at $1.98 on Wednesday. The company has a market capitalization of $51.68 million, a PE ratio of -0.94 and a beta of 0.89. Inovio Pharmaceuticals has a ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has entered into a definitive agreement to ...